Eribulin clinical trials
Also written E7389, Halaven and ER-086526.
Includes 2 studies of Liposomal Eribulin Mesylate.
How each study uses eribulin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eribulin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Nov 2010 · HALAVEN · NDA 201532 (FDA, Drugs@FDA)
- European Union
- 17 Mar 2011 · Halaven · EMEA/H/C/002084 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
127 studies that test it; most in 2014 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 12 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 12 |
| 2012 | 9 |
| 2013 | 7 |
| 2014 | 13 |
| 2015 | 8 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 10 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 48 · Other 79
Eisai Inc. (29) · National Cancer Institute (NCI) (13) · Eisai Co., Ltd. (7) · Dana-Farber Cancer Institute (5) · Eisai Limited (5) · M.D. Anderson Cancer Center (4) · MedSIR (3) · Sichuan Baili Pharmaceutical Co., Ltd. (2)
Often tested with
Tested in the same studies.
Gemcitabine (7) · Capecitabine (6) · Carboplatin (5) · Vinorelbine (4) · Trastuzumab (4) · Cyclophosphamide (4) · Pembrolizumab (4) · Irinotecan (4)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 12 phase 3 studies under way
Eribulin is the comparator. A study of two new drugs counts under both.
- 2Sacituzumab tirumotecan · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · next primary completion Dec 2026
- 2Datopotamab deruxtecan · AstraZeneca
- 1Trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd.
- 1Sacituzumab govitecan · Gilead Sciences · next primary completion Dec 2026
- 1Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 · Intensity Therapeutics, Inc. · next primary completion Dec 2027
- 1Beruzatatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · next primary completion Dec 2027
- 1Anbenitamab repodatecan · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- 1Fluzoparib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Mar 2031
Reaching primary completion within a year · 5
Studies that test eribulin.
- Dec 2026Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Phase 2 · Sun Yat-sen University
- Dec 2026A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid TumorsPhase 1 · M.D. Anderson Cancer Center
- Mar 2027A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorPhase 1/2 · Eisai Co., Ltd.
- Jun 2027Tucatinib+Trastuzumab+Eribulin in HER2+ MBCPhase 2 · Criterium, Inc.
- Nov 2027Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerPhase 2 · Xijing Hospital
Studies
Open first, then newest update. How each study uses eribulin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 127
- Scalp Cooling in MBCRecruitingPhase 2Dana-Farber Cancer InstituteNCT04986579Written as Eribulin
- A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid TumorsRecruitingPhase 1M.D. Anderson Cancer CenterNCT06006273Written as Eribulin
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06889688Written as Camrelizumab+Apatinib+Eribulin
- A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug ConjugatesRecruitingPhase 2Sun Yat-sen UniversityNCT07520760Written as Eribulin in Combination with Anlotinib
- A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA MutationNot yet recruitingPhase 2Hu HaiNCT07441512Written as Inavolisib in Combination With Eribulin
- Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07333937Written as Neratinib Combined with Fulvestrant and Eribulin
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07255612Written as Eribulin
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney DysfunctionActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT00365157Written as Eribulin Mesylate
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04579224Written as Eribulin Mesylate
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerCompletedPhase 1City of Hope Medical CenterNCT02120469Written as eribulin mesylate
- A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingPhase 1/2Eisai Co., Ltd.NCT04078295Written as E7389-LF
- Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain TumorsCompletedEarly Phase 1City of Hope Medical CenterNCT02338037Written as Eribulin Mesylate
- Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)CompletedPhase 2Massachusetts General HospitalNCT03331250Written as Eribulin
- Study of E7389 Liposomal Formulation in Participants With Solid TumorActive, not recruitingPhase 1Eisai Co., Ltd.NCT03207672Written as E7389-LF
- EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaCompletedPhase 2Australia New Zealand Gynaecological Oncology GroupNCT05619913Written as Eribulin Mesylate
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)Active, not recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06343948Written as Eribulin
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Active, not recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382142Written as Eribulin
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingPhase 2Criterium, Inc.NCT05458674Written as Eribulin
- A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02623972Written as Eribulin
- Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03202316Written as Eribulin
See all 127 studies that test eribulin →
Given beside what is tested · 44 — eribulin is usual care or a partner of the new treatment
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingPhase 2ALX Oncology Inc.NCT07007559Written as Eribulin
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingPhase 3BioNTech SENCT07173751Written as Eribulin
- A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07824869Written as Eribulin
- A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNot yet recruitingPhase 1/2Advenchen Pharmaceuticals, LLC.NCT07811232Written as Eribulin
- A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05570253Written as Eribulin
- Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingPhase 1Washington University School of MedicineNCT06957431Written as Eribulin
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNot yet recruitingPhase 1/2MedSIRNCT07494448Written as Eribulin Mesilate injection
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06435429Written as Eribulin
- A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingPhase 2Fudan UniversityNCT07205185Written as QL1706 + Eribulin + Anlotinib + Radiotherapy
- Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast CancerRecruitingPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06942234Written as Eribulin
- JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingPhase 2Fudan UniversityNCT06731153Written as Eribulin
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)RecruitingPhase 1/2GI Innovation, Inc.NCT05824975Written as eribulin
- Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerNot yet recruitingPhase 2Wang JiayuNCT06539559Written as Eribulin
- LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06387628Written as Eribulin
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06355037Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNot yet recruitingPhase 2Zhejiang Cancer HospitalNCT06308939Written as Eribulin
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06202261Written as Eribulin mesylate injection
- Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNot yet recruitingPhase 2Shengjing HospitalNCT06202313Written as Eribulin
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03237780Written as Eribulin Mesylate
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04345913Written as Eribulin Mesylate
Showing 20 of 44.
As the comparator · 23 — what is tested is compared with eribulin
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)RecruitingPhase 3Intensity Therapeutics, Inc.NCT06263231Written as Eribulin
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454Written as Eribulin
- Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06081959Written as Eribulin
- Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast CancerRecruitingPhase 2Seoul National University HospitalNCT05530057Written as Eribulin Mesylate
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06079983Written as Eribulin mesylate injection
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06255392Written as Eribulin mesylate injection
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824Written as Eribulin
- Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast CancerRecruitingPhase 3Sun Yat-sen UniversityNCT06268652Written as Eribulin
- A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06279364Written as Eribulin
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786Written as Eribulin
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedPhase 3Daiichi SankyoNCT03734029Written as Eribulin
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active, not recruitingPhase 3AstraZenecaNCT05104866Written as Eribulin
- SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical TrialActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05814354Written as Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active, not recruitingPhase 3AstraZenecaNCT05374512Written as Eribulin mesylate
- Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Active, not recruitingPhase 3Gilead SciencesNCT04639986Written as Eribulin Mesylate Injection
- FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingPhase 3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06519370Written as Eribulin
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as Eribulin
- Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerStatus unknownPhase 3Shanghai Yizhong Pharmaceutical Co., Ltd.NCT06143553Written as Eribulin Mesilate injection
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerCompletedPhase 3Gilead SciencesNCT03901339Written as Eribulin
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineCompletedPhase 3Nektar TherapeuticsNCT02915744Written as Eribulin
Showing 20 of 23.
Codes
What other systems call eribulin · ClinicalTrials.gg INT004696
- MeSH (NLM) C490954eribulinConfirmed NLM, Wikidata
- UNII (FDA) LR24G6354GERIBULINConfirmed FDA, NLM, Wikidata
- RxNorm 1045453Confirmed FDA, Wikidata
- Wikidata Q408717eribulinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96748EribulinOne source FDA
- DrugBank DB08871One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C490954 | eribulin | Confirmed NLM, Wikidata |
| UNII (FDA) | LR24G6354G | ERIBULIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1045453 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408717 | eribulin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96748 | Eribulin | One source FDA |
| DrugBank | DB08871 | — | One source Wikidata |
Also registered as eribulin mesylate (UNII AV9U0660CW · RxNorm 1045452).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.